• <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    来宝网Logo

    热门词:生物显微镜 水质?#27835;?#20202; 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置首页>技术资料首页>行业动态>公司动态>2008年罗氏以1.25亿美元收购RNAi和基因治疗公司Mirus

    2008年罗氏以1.25亿美元收购RNAi和基因治疗公司Mirus

    罗氏2010年8月6日 19:18 点击:2474




    美国Mirus Bio   瑞士罗氏Roche

    罗氏和Mirus Bio公司今天宣布罗氏将收购全面Mirus Bio公司。后者是一家总部设在威斯康星州麦迪逊的私有公司,主要致力于探索和开发创新的核酸技术,包括专利的RNAi转运平台。
     

    RNAi是一种体内沉默某种基因的天然机制,它为难治愈的疾病带来了新的希望。这项技术目前遇到的最大挑战就是如何将RNAi分子准确运送到靶细胞。Mirus的转运平台提供了一种创新的方法,能?#34892;?#22320;对特定疾病靶点实施RNAi疗法。
     

    罗氏的使命是为难治愈疾病的患者提供新的解决方案。RNAi疗法?#26143;?#21147;治疗复杂的疾病如癌症、呼吸或代谢紊乱。在2007年,罗氏曾宣布与美国Alnylam Pharmaceuticals公司结盟,还收购了Alnylam位于德国的研究基地。这也就是现在罗氏开发RNAi治疗药物的卓越?#34892;模–entre of Excellence)。
     

    罗氏制药研?#24247;?#20840;球总裁Lee E. Babiss表示,Mirus的科学?#20197;赗NAi转运方面的开拓性研究,加上我们的RNAi研究卓越?#34892;模?#23558;使罗氏站在新疗法的最前线。我们的全球研究团队在推进RNAi治疗方面已经取得了很大的进步,这些新同事将使我们如虎添翼。Mirus带来的技术以及其他技术会让我们创造出更?#34892;?#30340;RNAi疗法。
     

    Mirus总裁Russell R. Smestad表示,罗氏在RNAi领域的技能、资源和?#20449;担?#20351;它成为Mirus的理想伙伴。我们的联合将大大加速研究进程。
     

    根据协议的条款,罗氏将以1.25亿美元全面收购Mirus,并保留麦迪逊的RNAi研究?#34892;摹irus的转染试剂业务将拆分成独立的业务,称为Mirus Bio LLC,对现有的客户没有任何预期影响。交易的完成时间将取决于标准条件,预计将在2008年下半年结束。
     

    关于Mirus Bio公司
    Mirus Bio公司是RNA干扰和基因治疗领域的领先者。该公司的Dynamic PolyConjugates技术改良后能成为siRNA疗法的平台。在基因治疗方面,该公司通过专利的Pathway IV hydro- dynamic delivery平台开发了全新的人类疗法。主要项目是与Transgene S.A.合作开发的肌肉萎缩症治疗。另外,Mirus还推出了最先进的DNA和siRNA转染、标记产品。更详细的信息请访问www.mirusbio.com。
     

    关于罗氏
    总部设在瑞士巴塞尔的罗氏,是一个世界领先的、注重科研的医药和诊断产品开发集团。作为世界上最大的生物技术公司,该集团为疾病的早期发现、预防、诊断和治疗提供了创新产品和服务,在改善人类健康和生活质?#24247;?#21508;个方面都做出了大量贡献。罗氏公司是体外诊断的世界领先公司,是治疗癌症和器官移植所需药物的领先供应者,也是病毒学的市场领导者,并活跃在其他主要的治疗领域,如自身免疫性疾病,炎症,代?#24739;?#20013;枢神经系?#22330;?007年该集团药品部的销售总额为368亿瑞士法郎,诊断部的销售额为93亿瑞士法郎。罗氏公司与众多的合作伙伴签订?#25628;?#21457;协议并结成战略联盟,包括在美国基因技术公司(Genentech, Inc.)和日本中外制药株式会社(Chugai Pharmaceutical Co., Ltd.)拥有多数股权,2007年研发投资达80亿瑞士法郎。罗氏集团的全球员工总数约8万。如需?#31169;?#26356;详细的信息,请访问我们的网站www.roche.com。
     

     

    Roche acquires Mirus to advance research in the field of RNAi delivery

    MADISON, WI, USA, July 22, 2008 – Mirus Bio Corporation and Roche (Basel, Switzerland) announced today that they have entered into a definitive agreement under which Roche will acquire Mirus Bio Corporation, a privately-owned US company based in Madison, Wisconsin, that focuses on the discovery and development of innovative nucleic acid based technologies, including a proprietary RNAi (Ribonucleic Acid interference) delivery platform.

    RNAi – a natural mechanism that the body uses to ‘silence’ certain genes – represents a potential whole new class of therapeutics for difficult to treat diseases. The major challenge of this promising technology has so far been the transport of RNAi molecules into the target cell. Mirus’ delivery platform provides an innovative way of effectively getting RNAi therapeutics to specific disease targets.

    Roche’s mission is to find novel solutions for patients who suffer from difficult to treat diseases. RNAi therapeutics provides the capabilities to target complex diseases such as cancer, respiratory or metabolic disorders. In 2007, Roche already announced a major alliance with the US-based company Alnylam Pharmaceuticals, Inc., which included the acquisition of Alnylam’s European research site located in Kulmbach, Germany. This is now Roche’s established Centre of Excellence for RNAi therapeutic research.

    "The pioneering work in RNAi delivery by the scientists at Mirus, together with our Centre of Excellence for RNAi research in Kulmbach, puts Roche at the forefront of bringing this whole new class of treatment to patients who suffer from difficult to treat diseases," said Lee E. Babiss, Global Head of Roche Pharma Research. "Our global research team has made great strides in advancing RNAi therapeutics, and with our new colleagues in Madison we will now bolster those efforts. The technology brought by Mirus, together with additional technologies, will bring us closer to creating fully enabled RNAi therapeutics."

    "The expertise, resources and commitment that Roche brings to the RNAi field make Roche an ideal partner for Mirus," said Russell R. Smestad, President of Mirus. "Together we will be able to greatly accelerate the progress we would have accomplished independently."

    Under the terms of the agreement, Roche will fully acquire Mirus for USD 125 million and will maintain an RNAi research site in Madison. Mirus’ transfection reagents business will be divested into a standalone business to be known as Mirus Bio LLC, without any anticipated effect on existing customers. Employees will be offered a TransITion into their respective business unit. Closing of the transaction is subject to standard conditions. Completion is expected during the second half of 2008. Advisors to Mirus for this transaction were JMP Securities LLC and Quarles & Brady LLP.

    About RNAi
    RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells. Its discovery was awarded the Nobel Prize in October 2006. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. RNAi therapeutics targets the cause of diseases by potently silencing specific messenger RNAs (mRNAs), thereby preventing disease-causing proteins from being made. RNAi therapeutics has the potential to treat disease and help patients in a fundamentally new way.

    About Mirus Bio Corporation
    Mirus Bio Corporation is a leader in the fields of RNA interference and gene therapy, based upon its expertise in nucleic acid chemistry and delivery. The company’s Dynamic PolyConjugates™ technology is being refined as an enabling platform for siRNA therapeutics. In gene therapy, the company is developing novel human therapeutics enabled by its proprietary Pathway IV™ hydrodynamic delivery platform. The lead program is a treatment for Muscular Dystrophy, which is being developed collaboratively with Transgene S.A. of Strasbourg, France. Finally, the company currently markets state-of-the-art DNA and siRNA transfection and labeling products to researchers worldwide. Additional information is available at www.mirusbio.com.

    About Roche
    Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at www.roche.com.

    All trademarks used or mentioned in this release are protected by law.

    Roche Group Media Relations
    Telephone: +41 61 688 8888 / Email: [email protected]
    - Daniel Piller (Head)
    - Alexander Klauser
    - Claudia Schmitt
    - Martina Rupp
    - Nina Schwab-Hautzinger

    Corporate Contact:
    Russell Smestad, President
    +1.608.238.4400
    [email protected]



    View PDF

    (来源: 罗氏 )


    全年征稿 / 资讯合作

    联系?#27663;洌簁[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.67994619.com,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,?#24247;?#22312;于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载?#20445;?#24517;须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权?#20219;?#39064;,请在作品发表之日起一周内与本网联系,否则视为?#29260;?#30456;关权利。


    云南11选5技巧
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    江苏快三开奖直播 二八杠怎样瞬间变牌 私彩广西快乐十分 吉林快3推荐预测号 广东十一选五全天计划 香港赛马会心水资料大全 新11选5是什么软件 青海快三走势图带连线 多乐彩走势图解 曾道人救世网期期开奖 河北时时彩玩法 期特码公开 大乐透在电视开奖直播 福建快三一百期内开奖走势图 象棋2019下载